All In Biotech

Drug Trial Radar · NCT07093710

Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

The Safety and Efficacy of Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma: A Prospective, Multicenter, Open-label, Phase Ib/II Clinical Study

Last checked: Nov 20, 2026Latest source record: Dec 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

101

Planned (sponsor's estimate)

Start

Aug 27, 2025

Primary completion

Aug 1, 2027

Study completion Aug 1, 2029

Sponsor

Lead sponsor
Sun Yat-sen UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 30, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, multicenter, open-label, phase Ib/II clinical study to evaluate the safety and efficacy of golidocitinib combined with mitoxantrone hydrochloride liposome or chidamide in the treatment of relapsed or refractory peripheral T-cell lymphoma

Conditions

  • Peripheral T Cell Lymphoma

Interventions

  • GolidocitinibDrug

    150mg, po, qd;

  • Mitoxantrone Hydrochloride LiposomeDrug

    Cohort 1: 15 mg/m2, IV, D1 and 18 mg/m2, IV, D1 (phase Ib); RP2D (II study)

  • ChidamideDrug

    Cohort 2: Chidamide:20mg/30mg, po, Biw (phase Ib); RP2D (phase II study)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall response rate(ORR) for Phase 2Time frame: Up to 24 months
  2. Maximum tolerated dose (MTD) for Phase 1bTime frame: The first cycle after administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.